Qiagen (QGEN) announced that the FDA has cleared the QIAstat-Dx Respiratory Panel Mini test for clinical use. It is the third test to receive FDA clearance for use with QIAstat-Dx systems in 2024. The QIAstat-Dx Respiratory Panel Mini is designed to support clinical decision making in diagnosing upper respiratory infections in outpatient settings and covers five common viral causes of illness: influenza A, influenza B, human rhinovirus, respiratory syncytial virus and SARS-CoV-2.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on QGEN:
- Qiagen downgraded to Hold from Buy at HSBC
- Qiagen expands automated liquid biopsy portfolio
- Neogen appoints Bernard to the board of directors
- Qiagen gets European IVDR certification
- Qiagen, Bode team to advance GEDmatch PRO forensic genealogy database
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
